Key Drivers
- Improved margins
- Falling cash/earnings
- High leverage/inventory
AIAI Summary
PAHC is no longer a pure organic growth story but an acquisition-driven consolidation play where near-term valuation hinges on execution of MFA/Phibro integration, inventory conversion, and sustained free cash flow rather than headline revenue — so prioritize monitoring quarter-to-quarter FCF, inventory burn rates, and net leverage trajectory over revenue growth. The key actionable risk: failure to convert $517M of inventory and volatile FCF would quickly reverse recent margin gains and force capital allocation toward debt reduction, pressuring upside; require consecutive quarters of falling net leverage and positive FCF conversion to upgrade the thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Improved margins
- •Falling cash/earnings
- •High leverage/inventory
PAHC's operating profitability improved (EBITDA margin up, EV/EBITDA tightened) but falling net income and FCF, very high leverage and inventory concentration create material bottom‑line, cash and solvency risks.
Price Behavior
Key Price Behavior Insights:
- •Below last month MA
- •Support in high‑$40s
- •Lower highs trend
PAHC is trading below its last month simple moving average (~$51.44), showing a short-term downtrend with support at $47.92 and $49–$50 but resistance near ~$54.5 and a risk of retesting the March low if momentum fades.
Rapid run from ~$40 in early
Sentiment & News
Key News Insights:
- •Citigroup stake
- •Analyst upgrades
- •CEO partial sell
Late Feb–Mar 2026 saw Citigroup more than double its PAHC stake amid broad Strong Buy/GARP/low‑PEG analyst attention while CEO Jack Bendheim indirectly sold ~14,080 shares (~20.8% of his holdings), signaling rising institutional interest but notable insider selling.
Mixed signals—strong institutional inflows and positive analyst positioning could underpin the stock, but meaningful insider selling may limit near‑term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings